<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912336</url>
  </required_header>
  <id_info>
    <org_study_id>BC-07099</org_study_id>
    <nct_id>NCT04912336</nct_id>
  </id_info>
  <brief_title>Extracorporeal Life Support and Modification of Hemostasis</brief_title>
  <acronym>ELMOH</acronym>
  <official_title>Extra Corporeal Life Support and Modification of Hemostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate change in coagulation tests during a 48-h period after initiation VV-ECMO and&#xD;
      VA-ECMO.&#xD;
&#xD;
      (ECMO= Extra Corporeal Membrane Oxygenator) Assessment of bleeding during Veno-Venous&#xD;
      Extracoporeal Membrane Oxygenator (VV-ECMO) and Veno-Arterial Extracoporeal Membrane&#xD;
      Oxygenator (VA-ECMO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, pilot cohort study, performed in the Intensive Care&#xD;
      Units (ICUs) of the Ghent University Hospital, CHU Liège, University Hospital Brussels, and&#xD;
      University Hospital Munster.&#xD;
&#xD;
      Each group will contain 20 subjects; in total there will be 40 subjects 2 groups of 20&#xD;
      patients GROUP 1: VV-ECMO n = 20 GROUP 2: VA-ECMO n = 20&#xD;
&#xD;
        -  Demographics: age, sex, comorbidities, medication, reason for ECMO therapy&#xD;
&#xD;
        -  Simplified Acute Physiology Score (SAPS) 3 at time of ICU admission.&#xD;
&#xD;
        -  Components of the Sequential Organ Failure Assessment score daily (based on worst value&#xD;
           of each component of the score)&#xD;
&#xD;
        -  ECMO characteristics (place of cannulation, type of cannulas, oxygenator, bloodflow,&#xD;
           gasflow and pressure registrations)&#xD;
&#xD;
        -  Incidence and severity of bleeding, scored according to the GUSTO and BARC scores&#xD;
&#xD;
        -  Coagulation profile: At inclusion (before heparine infusion is started), 2h after start&#xD;
           of therapy, 24h, and 48h, and at specific moments of clinical suspicion of profound&#xD;
           altered hemostasis. We defined a coagulation profile as a set of tests that includes&#xD;
&#xD;
             -  prothrombin time (PT), international normalized ratio (INR)&#xD;
&#xD;
             -  activated partial thromboplastin time (aPTT) and heparin ratio&#xD;
&#xD;
             -  the fibrinogen level&#xD;
&#xD;
             -  platelets&#xD;
&#xD;
             -  ACT (iACT®, …)&#xD;
&#xD;
             -  D-dimer&#xD;
&#xD;
             -  ROTEM (extem, intem, heptem) or TEG (Utrecht)&#xD;
&#xD;
             -  AT III&#xD;
&#xD;
             -  anti Xa&#xD;
&#xD;
        -  Temperature daily (H/L) (core)&#xD;
&#xD;
        -  Patient characteristics that may influence coagulation or the results of coagulation&#xD;
           tests: body weight, Body Mass Index, drugs, C-reactive protein (as a marker for&#xD;
           inflammation), Hemoglobin level, LDH, unconjugated bilirubin, (or haptoglobine or plasma&#xD;
           free haemoglobin, if tested)&#xD;
&#xD;
        -  Heparin dose&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>48 hours</time_frame>
    <description>Moderate thrombocytopenia lower than 150 x 103/µL in 25% of recruited patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding problems, Type 2 Bleeding according to BARC criteria or moderate bleeding according to GUSTO criteria</measure>
    <time_frame>48 hours</time_frame>
    <description>incidence of clinical overt bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clotting problems</measure>
    <time_frame>48 hours</time_frame>
    <description>Incidence of deep venous trombosis or emboli or ECMO circuit problems due to clotting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusion</measure>
    <time_frame>48 hours</time_frame>
    <description>Need for transfusion of packed red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visco-elastic testing</measure>
    <time_frame>At 2 hours, 24 hours, 48 hours</time_frame>
    <description>ROTEM changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>survival in the ICU, in the hospital, at day 28, day 90, 6months and 1 year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bleeding Disorder</condition>
  <condition>Extra Corporeal Life Support</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>VV-ECMO</arm_group_label>
    <description>Patients supported because of respiratory failure by Veno-Venous Extra Corporeal Membrane Oxygenator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VA-ECMO</arm_group_label>
    <description>Patients supported because of circulatory failure by Veno-Arterial Extra Corporeal Membrane Oxygenator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard coagulation profile</intervention_name>
    <description>prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount</description>
    <arm_group_label>VA-ECMO</arm_group_label>
    <arm_group_label>VV-ECMO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Specific coagulation tests</intervention_name>
    <description>AT III, anti Xa, ACT, ROTEM</description>
    <arm_group_label>VA-ECMO</arm_group_label>
    <arm_group_label>VV-ECMO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bleeding Scores</intervention_name>
    <description>Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)</description>
    <arm_group_label>VA-ECMO</arm_group_label>
    <arm_group_label>VV-ECMO</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood tests for coagulation parameters&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  GROUP 1: patients who will be initiated on VV-ECMO within a 12-h period&#xD;
&#xD;
          -  GROUP 2: patients who will be initiated on VA-ECMO within a 12-h period&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GROUP 1: patients who will be initiated on VV-ECMO within a 12-h period&#xD;
&#xD;
          -  GROUP 2: patients who will be initiated on VA-ECMO within a 12-h period&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Signed Informed Consent, signed by subject or authorized representative&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Expected survival &lt;48-h Known coagulopathy Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harlinde Peperstraete, MD</last_name>
    <phone>+32 93325185</phone>
    <email>harlinde.peperstraete@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Hoste, MD PhD</last_name>
    <phone>+32 9 3324197</phone>
    <email>eric.hoste@ugent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harlinde Peperstraete, MD</last_name>
      <phone>93325185</phone>
      <email>harlinde.peperstraete@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Raes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Liege</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Massion, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Meersch, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>All data will be put in Redcap. At inclusion, at inclusion +2h, at inclusion +24 and at inclusion +48h: a clotting panel and clinical observation about bleedina and clotting will be performed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

